Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
about
Cardiovascular riskEvaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistancesThe associations between serum biomarkers and stenosis of the coronary arteriesRole of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome.Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndromeNeutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement.The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trialsCystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study.Screening for suspected coronary heart disease in patients, using integrated serum biochemical indices.IL-34 is associated with the presence and severity of renal dysfunction and coronary artery disease in patients with heart failureBiomarkers in outpatient heart failure management; Are they correlated to and do they influence clinical judgment?Therapeutic implications of biomarkers in chronic heart failure.Epidemiology and importance of renal dysfunction in heart failure patients.Serum Cystatin C and the Risk of Coronary Heart Disease in Ethnic Chinese Patients With Normal Renal Function.The ZDSD rat: a novel model of diabetic nephropathy.Isolation and characterization of autoantibodies against human cystatin C.Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly.
P2860
Q26825634-2B029165-98DB-4C96-9A19-C0F9153DFAC1Q28084462-30F4FF29-9A2D-4AD3-9A2B-8BF7EAF36254Q28554584-1762D616-F0F9-4343-8954-BE762711BF36Q33768050-77A3AE21-D2D0-491C-80AE-410C93FC1B5BQ33977297-53F6A35A-CCE5-46FD-BF47-C1A0B4F05A3CQ34616632-0E0B8EE8-EB58-488A-AD38-D37EDB4FA3C6Q35672997-39C98EDB-1C3B-4981-81B2-C9C1CF8D20CAQ36103793-936616E0-1B61-4ACC-86CA-5E946B4DE771Q36577207-D8D03AE1-0BCB-420B-BFA8-A5D09EEFBC76Q37508213-0A205266-E7EF-4B45-A595-1801B37C5879Q37597779-03E12BD1-D808-4586-8CF1-40EEA797230CQ38121720-243E6E1B-B536-4795-BB13-BD3896F02571Q38149800-210C19AA-38BB-4081-A2E7-6BFA8BD68C5BQ40998882-194AED3F-1103-429B-8A3A-434CFED27F70Q41965910-1DA4E9F4-86D0-4D72-B209-580772C160E9Q48287384-41BCDF02-510C-4406-A47F-C7551D282366Q50222299-963D05D9-9C34-42A0-B5D4-7EE38B62F0AF
P2860
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@en
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@nl
type
label
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@en
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@nl
prefLabel
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@en
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@nl
P2860
P1476
Cystatin C: a step forward in assessing kidney function and cardiovascular risk.
@en
P2093
Johan Lassus
P2860
P2888
P304
P356
10.1007/S10741-011-9242-6
P577
2012-03-01T00:00:00Z